SGLT-2 inhibitors, a novel class of glucose-lowering drugs, have shown substantial cardiovascular and renal protective effects in patients with stage 1-4 CKD, regardless of the presence of diabetes. Here, SLC5A2 is linked to chronic kidney disease.